Entries by Dan Zapata

La Jolla Pharmaceutical Company Receives Orphan Drug Designation for Two Novel Compounds for Fibrodysplasia Ossificans Progressiva

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company(Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted La Jolla orphan drug designation for two […]

La Jolla Pharmaceutical Company and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors

Novel Compounds Have Therapeutic Potential in Broad Range of Diseases, Including Certain Rare Genetic Disorders SAN DIEGO & NASHVILLE, Tenn.–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, and Vanderbilt University (Vanderbilt) today announced […]

La Jolla Pharmaceutical Company Announces FDA Acceptance of IND for LJPC-401

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company(Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug Application (IND) for LJPC-401, La Jolla’s novel formulation of […]

La Jolla Pharmaceutical Company Announces Second Quarter 2015 Financial Results and Recent Corporate Progress

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported second quarter 2015 financial results and highlighted recent corporate progress. Recent Corporate Progress La Jolla initiated its ATHOS (Angiotensin II […]

La Jolla Pharmaceutical Company Announces Exclusive Worldwide License Agreements Covering LJPC-30Sa and LJPC-30Sb

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has signed two exclusive worldwide license agreements for the intellectual property rights covering La Jolla’s next-generation gentamicin derivatives, […]

Lakhmir S. Chawla, M.D. Receives the International Vicenza Award

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that Lakhmir “Mink” S. Chawla, M.D., the Company’s Chief Medical Officer, received the International Vicenza Award for Critical Care Nephrology at the […]

La Jolla Pharmaceutical Company to Provide Corporate Overview at the JMP Securities Life Science Conference 2015

La Jolla Pharmaceutical Company to Provide Corporate Overview at the JMP Securities Life Science Conference 2015 SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Company will […]

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2015 Global Healthcare Conference

May 27, 2015 01:01 PM Pacific Daylight Time SAN DIEGO–(BUSINESS WIRE)–La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla, […]

La Jolla Pharmaceutical Company Acquires Rights to Next-Generation Gentamicin Derivatives

May 7, 2015 20:17 UTC Conference Call and Webcast at 8:00 AM Eastern Time on Friday, May 8 SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has entered […]

La Jolla Pharmaceutical Company Announces Portfolio Reprioritization

May 7, 2015 20:11 UTC Conference Call and Webcast at 8:00 AM Eastern Time on Friday, May 8 SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced a reprioritization of its […]